GBR-401
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models.
For research use only. We do not sell to patients.
- CAS No.: 1931954-95-8
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
CD19
GBR-401 (0.00001-1 µg/mL, 4-24 h) displays a markedly superior ADCC activity on malignant B cells and primary CLL and lymphoma samples[1].
GBR-401 shows EC50 values of 1.2 ng/mL (Raji), 0.9 ng/mL (Ramos), 0.8 ng/mL (SU-DHL-6), 2 ng/mL (Namalwa), 1.6 ng/mL (B-CLL) and 15 ng/mL (Lymphoma) for ADCC[1].
GBR-401 (0.1-5 μg/mL, 2 h) results in a rapid increase in the proportion of late apoptotic/necrotic dead in Mec-1, Raji and SU-DHL-6 cell lines[1].
GBR-401 induces cell death by inducing a rapid and strong homotypic aggregation through actin reorganization in Raji cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
GBR-401 (0.005-10 mg/kg, i.p., a single dose) depletes B cells in human PBMCs cells xenograft mice models[1].
GBR-401 (2 mg/kg, i.p., a single dose) significantly reduces B-CLL cells in human CLL cells xenograft mice models[1].
GBR-401 (2 mg/kg, for 3 times at day 3, 7 and 10) prolongs median survival time and increases mice survival in Raji cells xenograft mice models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human PBMCs cells xenograft mice models (SCID mice, 8 weeks)[1]
-
Dosage:0.005, 0.02, 0.1, 0.5, 2 and 10 mg/kg
-
Administration:Intraperitoneal injection
-
Result:Showed an EC50 value of 0.03 mg/kg and a maximum efficacy from 2 mg/kg with 84% reduction of the B cell population after 4 days.
-
Animal Model:Patient derived CLL and purified NK cells from healthy donors xenograft mice models (SCID mice, 8 weeks)[1]
-
Dosage:2 mg/kg
-
Administration:Intraperitoneal injection
-
Result:Displayed a dramatic and significant reduction (92%) of B-CLL cells in the peritoneal cavity.
-
Animal Model:Raji cells xenograft mice models (SCID mice, 8 weeks)[1]
-
Dosage:2 mg/kg
-
Administration:for 3 times at day 3, 7 and 9
-
Result:Significantly prolonged median survival time (51 days) and increased mice survival by 2.1 fold.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1931954-95-8
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GBR-401 Related Classifications
HY-P991542 Related Classifications
Powered by Bioz